Myriad Genetics, Inc (NASDAQ:MYGN) has a beta value of 1.98 and has seen 1.85 million shares traded in the last trading session. The company, currently valued at $1.33B, closed the last trade at $17.83 per share which meant it lost -$0.16 on the day or -0.89% during that session. The MYGN stock price is -64.33% off its 52-week high price of $29.30 and 11.5% above the 52-week low of $15.78. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.79 million shares traded. The 3-month trading volume is 702.49K shares.

The consensus among analysts is that Myriad Genetics, Inc (MYGN) is Hold stock at the moment, with a recommendation rating of 2.62. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 5 out of 7 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.02.

Myriad Genetics, Inc (NASDAQ:MYGN) trade information

Sporting -0.89% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MYGN stock price touched $17.83 or saw a rise of 22.21%. Year-to-date, Myriad Genetics, Inc shares have moved -6.84%, while the 5-day performance has seen it change -18.81%. Over the past 30 days, the shares of Myriad Genetics, Inc (NASDAQ:MYGN) have changed -32.64%. Short interest in the company has seen 4.49 million shares shorted with days to cover at 6.48.

Wall Street analysts have a consensus price target for the stock at $29, which means that the shares’ value could jump 38.52% from current levels. The projected low price target is $22.0 while the price target rests at a high of $35.0. In that case, then, we find that the current price level is -96.3% off the targeted high while a plunge would see the stock gain -23.39% from current levels.

Myriad Genetics, Inc (MYGN) estimates and forecasts

Figures show that Myriad Genetics, Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -10.72% over the past 6 months, with this year growth rate of 137.04%, compared to 17.50% for the industry. Revenue growth from the last financial year stood is estimated to be 11.70%.

14 analysts offering their estimates for the company have set an average revenue estimate of 210.73M for the current quarter. 14 have an estimated revenue figure of 217.22M for the next ending quarter. Year-ago sales stood 191.9M and 196.6M respectively for this quarter and the next, and analysts expect sales will grow by 9.80% for the current quarter and 11.70% for the next.

Earnings growth for 2024 is a modest 135.73% while over the next 5 years, the company’s earnings are expected to increase by 57.00%.

MYGN Dividends

Myriad Genetics, Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Myriad Genetics, Inc (NASDAQ:MYGN)’s Major holders

Insiders own 2.02% of the company shares, while shares held by institutions stand at 104.24% with a share float percentage of 106.39%. Investors are also buoyed by the number of investors in a company, with Myriad Genetics, Inc having a total of 325.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 15.15 million shares worth more than $370.59 million. As of 2024-06-30, BLACKROCK INC. held 18.5369% of shares outstanding.

The other major institutional holder is VANGUARD GROUP INC, with the holding of over 10.06 million shares as of 2024-06-30. The firm’s total holdings are worth over $246.18 million and represent 12.314% of shares outstanding.